“…The evidence strongly supports distinct roles for both maternal Croen et al, 2008b;Singer et al, 2008;Zimmerman et al, 2007) and patient (Henneberg et al, 1994;Libbey and Fujinami, 2010;Ryberg, 1982) autoantibodies in ASD, including an ability to affect structural brain development (Nordahl et al, 2013;Rossi et al, 2011). Offending antibodies of either origin appear to persist systemically for extended periods of time Piras et al, 2014;Singer et al, 2006;Zimmerman et al, 2007), and although there exists a correlation between the two there does appear to be at least some differences in effect (Piras et al, 2014). Although reports indicate the presence of these antibodies may correlate with adverse conditions in the patients (Braunschweig et al, 2012a;Goines et al, 2011a;Mostafa and Al-Ayadhi, 2012;Piras et al, 2014), the nature of those connections needs to be further investigated, especially as regards different subpopulations of ASD.…”